Akademska digitalna zbirka SLovenije - logo
E-viri
Recenzirano Odprti dostop
  • A Comparison Between Optica...
    Inoue, Maiko; Jung, Jesse J; Balaratnasingam, Chandrakumar; Dansingani, Kunal K; Dhrami-Gavazi, Elona; Suzuki, Mihoko; de Carlo, Talisa E; Shahlaee, Abtin; Klufas, Michael A; El Maftouhi, Adil; Duker, Jay S; Ho, Allen C; Maftouhi, Maddalena Quaranta-El; Sarraf, David; Freund, K Bailey

    Investigative ophthalmology & visual science, 07/2016, Letnik: 57, Številka: 9
    Journal Article

    To determine the sensitivity of the combination of optical coherence tomography angiography (OCTA) and structural optical coherence tomography (OCT) for detecting type 1 neovascularization (NV) and to determine significant factors that preclude visualization of type 1 NV using OCTA. Multicenter, retrospective cohort study of 115 eyes from 100 patients with type 1 NV. A retrospective review of fluorescein (FA), OCT, and OCTA imaging was performed on a consecutive series of eyes with type 1 NV from five institutions. Unmasked graders utilized FA and structural OCT data to determine the diagnosis of type 1 NV. Masked graders evaluated FA data alone, en face OCTA data alone and combined en face OCTA and structural OCT data to determine the presence of type 1 NV. Sensitivity analyses were performed using combined FA and OCT data as the reference standard. A total of 105 eyes were diagnosed with type 1 NV using the reference. Of these, 90 (85.7%) could be detected using en face OCTA and structural OCT. The sensitivities of FA data alone and en face OCTA data alone for visualizing type 1 NV were the same (66.7%). Significant factors that precluded visualization of NV using en face OCTA included the height of pigment epithelial detachment, low signal strength, and treatment-naïve disease (P < 0.05, respectively). En face OCTA and structural OCT showed better detection of type 1 NV than either FA alone or en face OCTA alone. Combining en face OCTA and structural OCT information may therefore be a useful way to noninvasively diagnose and monitor the treatment of type 1 NV.